Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis
Authors
Keywords
-
Journal
Journal of Crohns & Colitis
Volume 12, Issue 2, Pages 245-257
Publisher
Oxford University Press (OUP)
Online
2017-10-20
DOI
10.1093/ecco-jcc/jjx143
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vedolizumab safety in pregnancy and newborn outcomes
- (2017) Mette Julsgaard et al. GUT
- Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
- (2017) Carlos Taxonera et al. INFLAMMATORY BOWEL DISEASES
- Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study
- (2017) Stephan R. Vavricka et al. INFLAMMATORY BOWEL DISEASES
- Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease
- (2017) Udayakumar Navaneethan et al. INFLAMMATORY BOWEL DISEASES
- Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience
- (2017) Uri Kopylov et al. INFLAMMATORY BOWEL DISEASES
- Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation
- (2017) Andrew P. Wright et al. LIVER TRANSPLANTATION
- Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
- (2017) Carl Eriksson et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Crohn’s disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know
- (2017) Parakkal Deepak et al. Abdominal Radiology
- Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis
- (2016) K. Hartery et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study
- (2016) D. C. Baumgart et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab
- (2016) B. Ungar et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
- (2016) A. Stallmach et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium
- (2016) Parambir S Dulai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2016) Bella Ungar et al. Clinical Gastroenterology and Hepatology
- Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease
- (2016) Aurelien Amiot et al. Clinical Gastroenterology and Hepatology
- Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease
- (2016) Namita Singh et al. INFLAMMATORY BOWEL DISEASES
- Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease
- (2016) Máire A. Conrad et al. INFLAMMATORY BOWEL DISEASES
- Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial
- (2016) Takayuki Matsumoto et al. Journal of Crohns & Colitis
- Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease
- (2016) Amy L. Lightner et al. Journal of Crohns & Colitis
- Loss of Response to Anti-TNFs: Definition, Epidemiology and Management
- (2016) Giulia Roda et al. Clinical and Translational Gastroenterology
- Pseudomonas Meningitis During Vedolizumab Therapy for Crohn’s Disease
- (2015) Brigid S. Boland et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled Trials
- (2015) Jennifer L. Jones et al. Clinical Gastroenterology and Hepatology
- Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
- (2015) Henit Yanai et al. Clinical Gastroenterology and Hepatology
- Vedolizumab for Induction and Maintenance of Remission in Ulcerative Colitis
- (2015) Mahmoud H. Mosli et al. INFLAMMATORY BOWEL DISEASES
- Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients
- (2015) Edward Shelton et al. INFLAMMATORY BOWEL DISEASES
- Management of Ulcerative Colitis Using Vedolizumab After Liver Transplantation for Primary Sclerosing Cholangitis
- (2015) Magdalena Meszaros et al. Journal of Crohns & Colitis
- Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice
- (2015) Emily E. Vivio et al. Journal of Crohns & Colitis
- Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure
- (2015) Bella Ungar et al. MEDICINE
- Vedolizumab for the treatment of ulcerative colitis
- (2015) Andreas Stallmach et al. Expert Review of Gastroenterology & Hepatology
- Loss of Response to Anti-Tumor Necrosis Factors: What Is the Next Step?
- (2014) Shomron Ben-Horin DIGESTIVE DISEASES
- Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
- (2014) Bruce E. Sands et al. GASTROENTEROLOGY
- Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies
- (2014) Mindy CW Lam et al. Immunotherapy
- Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis
- (2014) Uri Kopylov et al. Journal of Crohns & Colitis
- Tailoring anti-TNF therapy in IBD: drug levels and disease activity
- (2014) Shomron Ben-Horin et al. Nature Reviews Gastroenterology & Hepatology
- Optimizing anti-TNF treatments in inflammatory bowel disease
- (2013) Shomron Ben-Horin et al. AUTOIMMUNITY REVIEWS
- Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti–Tumor Necrosis Factor-α Agents
- (2013) Christine Kestens et al. Clinical Gastroenterology and Hepatology
- The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
- (2013) Bella Ungar et al. GUT
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease
- (2013) Manuel Barreiro-de-Acosta et al. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS
- Assessing Response and Loss of Response to Biological Therapies in IBD
- (2011) Henit Yanai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: Results from CARE
- (2011) Robert Löfberg et al. INFLAMMATORY BOWEL DISEASES
- Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study
- (2011) Asit Parikh et al. INFLAMMATORY BOWEL DISEASES
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More